AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9284668 — intervention group
Group type: COMPARATOR
Intervention: Continuation of diuretic treatment (control group, n = 100)
Number of subjects: 202
Study 9284668 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (withdrawal group)
Number of subjects: 202
Study 8141716 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered within six hours of symptom onset
Number of subjects: 0
Study 8141716 — intervention group
Group type: EXPERIMENTAL
Intervention: Public education on symptoms of myocardial infarction
Number of subjects: 0
Study 8141716 — intervention group
Group type: EXPERIMENTAL
Intervention: Expeditious transfer to hospital and assessment
Number of subjects: 0
Study 2881565 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 2881565 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study 31549623 — intervention group
Group type: EXPERIMENTAL
Intervention: Test (generic formulation)
Number of subjects: 64
Study 31549623 — intervention group
Group type: COMPARATOR
Intervention: Reference (branded formulation)
Number of subjects: 64
Study 30515480 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6‐mm long implants
Number of subjects: 60
Study 30515480 — intervention group
Group type: COMPARATOR
Intervention: 9.6‐mm or longer implants (augmented group)
Number of subjects: 60
Study 27342654 — intervention group
Group type: EXPERIMENTAL
Intervention: TGP 1800 mg/day and losartan 100 mg/day for 6 months
Number of subjects: 76
Study 27342654 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg/day for 6 months
Number of subjects: 76
Study 25410510 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based assessment
Number of subjects: 229
Study 25410510 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up
Number of subjects: 229
Study 22624409 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training (3 weeks, 2 times a week, 21 minutes per session)
Number of subjects: 18
Study 22624409 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E1 (workload at 45% to 65% of individual VO2max)
Number of subjects: 18
Study 22624409 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E2 (workload based on subjective evaluation of exertion, marked 4-6)
Number of subjects: 18
Study 22624409 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessment of exertion during training
Number of subjects: 18
Study 20026256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosomal Tacrolimus (5 mg/kg in rats, 10 mg/kg in mice)
Number of subjects: 2
Study 20026256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosomal Tacrolimus
Number of subjects: 2
Study 20026256 — intervention group
Group type: COMPARATOR
Intervention: Marketed HCO‐60 based Tacrolimus
Number of subjects: 2
Study 17572412 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% intravaginal gel
Number of subjects: 0
Study 17572412 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (IMP)
Number of subjects: 0
Study 15618441 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge and continued rehabilitation at home (ESD)
Number of subjects: 83
Study 15618441 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 83
Study 12614602 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage by the mother
Number of subjects: 0
Study 12614602 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (8.0 mg once daily for 4 weeks)
Number of subjects: 10
Study 10028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 10
Study 10028925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7567425 — intervention group
Group type: EXPERIMENTAL
Intervention: High visibility gratings with varying orientation, spatial frequency, and contrast
Number of subjects: 216
Study 7567425 — intervention group
Group type: COMPARATOR
Intervention: Single parameter variation (orientation, spatial frequency, or contrast)
Number of subjects: 216
Study 1975187 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 30
Study 1975187 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 30
Study 1975187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7337792 — intervention group
Group type: EXPERIMENTAL
Intervention: Study treatment assigned to private physicians (specific treatment details not available)
Number of subjects: 0
Study 30157976 — intervention group
Group type: EXPERIMENTAL
Intervention: PoNDER health visitor training
Number of subjects: 2241
Study 30157976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PoNDER HV training)
Number of subjects: 2241
Study 28233012 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised structured exercise programme (aerobic and resistance exercises performed bi-weekly, plus at least 30 min of brisk daily walks)
Number of subjects: 45
Study 28233012 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 45
Study 26347110 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after each chemotherapy infusion.
Number of subjects: 372
Study 26347110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin).
Number of subjects: 372
Study 23955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tri-weekly docetaxel (75 mg m(‐2) once tri-weekly) plus bicalutamide (50 mg once daily)
Number of subjects: 42
Study 23955552 — intervention group
Group type: COMPARATOR
Intervention: Continuous docetaxel without bicalutamide
Number of subjects: 42
Study 22338852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon colonoscopy (DBC)
Number of subjects: 58
Study 22338852 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 58
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 0.5 mg/kg
Number of subjects: 40
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 1 mg/kg
Number of subjects: 40
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 2 mg/kg
Number of subjects: 40
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 4 mg/kg
Number of subjects: 40
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 8 mg/kg
Number of subjects: 40
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA)
Number of subjects: 40
Study 19815876 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS)
Number of subjects: 40
Study 17174729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline thermal water
Number of subjects: 10
Study 17174729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline, chlorine-containing mineral water
Number of subjects: 10
Study 17174729 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 10
Study 15342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 0
Study 15342295 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 15342295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stenting and bypass grafting)
Number of subjects: 0
Study 11568036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (34 degrees C)
Number of subjects: 0
Study 11568036 — intervention group
Group type: COMPARATOR
Intervention: Control group (37 degrees C)
Number of subjects: 0
Study 9781417 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (generic tablet)
Number of subjects: 0
Study 9781417 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine (reference product)
Number of subjects: 0
Study 7816517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fructose (200 mg/kg, 20% solution, 2.5 min)
Number of subjects: 12
Study 3045842 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 124
Study 3045842 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 124
Study 3045842 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 20 mg
Number of subjects: 124
Study 3045842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 28977344 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25OHD) levels
Number of subjects: 5607
Study 28977344 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25OHD) levels in women
Number of subjects: 5607
Study 28977344 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25OHD) levels in men
Number of subjects: 5607
Study 28044135 — intervention group
Group type: EXPERIMENTAL
Intervention: ECVVH treatment for 72 hours
Number of subjects: 51
Study 28044135 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies without ECVVH
Number of subjects: 51
Study 24756361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg oxycodone (OXY)
Number of subjects: 24
Study 24756361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg oxycodone and 0.035 mg/kg naloxone solution (sOXN)
Number of subjects: 24
Study 24756361 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study 23270636 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate/Amodiaquine (AS+AQ) (Camoquin-Plus Paediatric®)
Number of subjects: 481
Study 23270636 — intervention group
Group type: COMPARATOR
Intervention: Artemether/Lumefantrine (AL) (Coartem®)
Number of subjects: 481
Study 23270636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AS+AQ and AL
Number of subjects: 481
Study 21044908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1197
Study 21044908 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 1197
Study 18551200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg/salmeterol 50 microg (F/S)
Number of subjects: 30
Study 18551200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg/salmeterol 50 microg plus montelukast 10 mg (F/S + M)
Number of subjects: 30
Study 18551200 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 15867282 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl
Number of subjects: 10
Study 15867282 — intervention group
Group type: EXPERIMENTAL
Intervention: all-rac-alpha-tocopheryl acetate
Number of subjects: 10
Study 15867282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RRR and all-rac treatments
Number of subjects: 10
Study 12906020 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice a week)
Number of subjects: 0
Study 12906020 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 10690146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 20
Study 10690146 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 20
Study 8942325 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1.5 g
Number of subjects: 60
Study 8942325 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg
Number of subjects: 60
Study 8942325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paracetamol 1.5 g and diclofenac 100 mg
Number of subjects: 60
Study 8942325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 1777736 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 45
Study 1777736 — intervention group
Group type: COMPARATOR
Intervention: MSI
Number of subjects: 45
Study 1777736 — intervention group
Group type: COMPARATOR
Intervention: AFSI
Number of subjects: 45
Study 7468959 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing of nitrous oxide, oxygen and halothane
Number of subjects: 2
Study 7468959 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation with fentanyl and alcuronium
Number of subjects: 2
Study 30523029 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2i users
Number of subjects: 1418
Study 30523029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin users
Number of subjects: 1418
Study 29444699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervically administered terlipressin
Number of subjects: 48
Study 29444699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27510521 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter
Number of subjects: 12
Study 27510521 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg twice daily
Number of subjects: 12
Study 27510521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23823711 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilisation training and traditional arm rehabilitation
Number of subjects: 27
Study 23823711 — intervention group
Group type: COMPARATOR
Intervention: Traditional arm rehabilitation alone
Number of subjects: 27
Study 22672917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy plus an oral care protocol
Number of subjects: 46
Study 22672917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (oral care protocol alone)
Number of subjects: 46
Study 19560157 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal radiography interpreted by pediatric emergency physicians
Number of subjects: 100
Study 17313289 — intervention group
Group type: EXPERIMENTAL
Intervention: Training 2 times per week, 3 sets of 10 repetitions to fatigue for 9 exercises
Number of subjects: 29
Study 17313289 — intervention group
Group type: EXPERIMENTAL
Intervention: Training 3 times per week, 2 sets of 10 repetitions to fatigue for 9 exercises
Number of subjects: 29
Study 15049152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lycopene (Tomatol) per day during 24 weeks
Number of subjects: 39
Study 15049152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12204864 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 77
Study 12204864 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77
Study 12204864 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who quit at the beginning of the LHS
Number of subjects: 77
Study 12204864 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who quit at the beginning of the LHS
Number of subjects: 77
Study 12204864 — intervention group
Group type: EXPERIMENTAL
Intervention: Men continuing to smoke throughout the 11 years
Number of subjects: 77
Study 12204864 — intervention group
Group type: EXPERIMENTAL
Intervention: Women continuing to smoke throughout the 11 years
Number of subjects: 77
Study 12204864 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 77
Study 12204864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 77
Study 9814452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary milk supplementation (D-4 glasses of milk/day)
Number of subjects: 60
Study 9814452 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3-1000 mg/day in two divided doses)
Number of subjects: 60
Study 9814452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7658265 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc glucoheptonate renal scan (GHS)
Number of subjects: 50
Study 7658265 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal ultrasonography (RUS)
Number of subjects: 50
Study 7658265 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrography (VCUG)
Number of subjects: 50
Study 7658265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GHS and VCUG
Number of subjects: 50
Study 2713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmet (osmotic pumping device)
Number of subjects: 9
Study 2713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation
Number of subjects: 9
Study 2713213 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitrendipine
Number of subjects: 9
Study 70929 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-light alone (313 nm)
Number of subjects: 0
Study 70929 — intervention group
Group type: EXPERIMENTAL
Intervention: Trioxsalen plus UV-light (365 nm)
Number of subjects: 0
Study 70929 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar plus UV-light (365 nm)
Number of subjects: 0
Study 70929 — intervention group
Group type: COMPARATOR
Intervention: UV-light alone (365 nm)
Number of subjects: 0
Study 70929 — intervention group
Group type: COMPARATOR
Intervention: Coal tar alone
Number of subjects: 0
Study 70929 — intervention group
Group type: COMPARATOR
Intervention: UV-light (405 nm)
Number of subjects: 0
Study 30295425 — intervention group
Group type: EXPERIMENTAL
Intervention: FIN-RACo + IFX
Number of subjects: 99
Study 30295425 — intervention group
Group type: COMPARATOR
Intervention: FIN-RACo + placebo
Number of subjects: 99
Study 29066265 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab plus standard of care (SOC)
Number of subjects: 440
Study 29066265 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 440
Study 29066265 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab plus SOC
Number of subjects: 440
Study 25361982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)/leucovorin
Number of subjects: 1254
Study 25361982 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 1254
Study 24114862 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group (n=39) earned vouchers based on video confirmation of breath CO ≤ 4 ppm
Number of subjects: 77
Study 24114862 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent group (n=38) earned vouchers independent of CO levels
Number of subjects: 77
Study 24114862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (contingent and noncontingent)
Number of subjects: 77
Study 24114862 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group
Number of subjects: 77
Study 24114862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 21593118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 750 mg dose of metyrapone
Number of subjects: 0
Study 21593118 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 750 mg dose of metyrapone
Number of subjects: 0
Study 21593118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19331224 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU epoetin-alpha thrice weekly
Number of subjects: 399
Study 19331224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epoetin-alpha)
Number of subjects: 399
Study 16504956 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% sage spray (140 microl sage extract per dose)
Number of subjects: 286
Study 16504956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 15276496 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus transmyocardial revascularization (CABG/TMR)
Number of subjects: 218
Study 15276496 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 218
Study 10904284 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (35 mg/day)
Number of subjects: 46
Study 10904284 — intervention group
Group type: COMPARATOR
Intervention: Losartan (175 mg/day)
Number of subjects: 46
Study 10904284 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + Losartan (15 mg + 100 mg/day)
Number of subjects: 46
Study 9060552 — intervention group
Group type: EXPERIMENTAL
Intervention: prednimustine 200 mg/m2/d for 5 days per month for 18 months
Number of subjects: 193
Study 9060552 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon alfa 5 MU/d for 3 months then 5 MU three times per week for 15 months
Number of subjects: 193
Study 9060552 — intervention group
Group type: COMPARATOR
Intervention: no initial treatment
Number of subjects: 193
Study 9060552 — intervention group
Group type: EXPERIMENTAL
Intervention: prednimustine
Number of subjects: 193
Study 9060552 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon alfa
Number of subjects: 193
Study 9060552 — intervention group
Group type: EXPERIMENTAL
Intervention: progression within 1 year
Number of subjects: 193
Study 8462390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 27
Study 8462390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2939208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13
Study 2939208 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 2939208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28919130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) + treatment-as-usual (TAU)
Number of subjects: 96
Study 28919130 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual (TAU) alone
Number of subjects: 96
Study 30201930 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace sitting-reduction intervention with activity tracker
Number of subjects: 153
Study 30201930 — intervention group
Group type: COMPARATOR
Intervention: Workplace sitting-reduction intervention without activity tracker
Number of subjects: 153
Study 30201930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting reduction (h/10 h at work)
Number of subjects: 153
Study 27959713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months
Number of subjects: 2124
Study 27959713 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months
Number of subjects: 2124